Janney Montgomery Scott LLC cut its stake in shares of Sensus Healthcare, Inc. (NASDAQ:SRTS – Get Rating) by 10.0% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 40,576 shares of the company’s stock after selling 4,500 shares during the period. Janney Montgomery Scott LLC owned approximately 0.25% of Sensus Healthcare worth $508,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently bought and sold shares of SRTS. Bank of New York Mellon Corp acquired a new position in Sensus Healthcare during the 1st quarter worth approximately $409,000. Dimensional Fund Advisors LP lifted its position in Sensus Healthcare by 92.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 131,453 shares of the company’s stock worth $1,330,000 after acquiring an additional 63,155 shares in the last quarter. Sei Investments Co. acquired a new position in Sensus Healthcare during the 1st quarter worth approximately $216,000. Vanguard Group Inc. lifted its position in Sensus Healthcare by 24.3% during the 1st quarter. Vanguard Group Inc. now owns 596,224 shares of the company’s stock worth $6,034,000 after acquiring an additional 116,409 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership acquired a new position in Sensus Healthcare during the 1st quarter worth approximately $285,000. 36.25% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Several equities analysts recently commented on SRTS shares. TheStreet lowered Sensus Healthcare from a “b” rating to a “c+” rating in a research report on Friday, November 4th. Alliance Global Partners decreased their price target on shares of Sensus Healthcare from $17.50 to $16.50 and set a “buy” rating for the company in a research report on Friday, November 4th.
Sensus Healthcare Stock Performance
Sensus Healthcare (NASDAQ:SRTS – Get Rating) last released its earnings results on Thursday, November 3rd. The company reported $0.11 earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.01). The company had revenue of $9.01 million during the quarter, compared to the consensus estimate of $8.92 million. Sensus Healthcare had a return on equity of 34.75% and a net margin of 60.14%. As a group, sell-side analysts expect that Sensus Healthcare, Inc. will post 0.79 earnings per share for the current fiscal year.
About Sensus Healthcare
Sensus Healthcare, Inc operates as a medical device company, which provides treatments for both oncological and non-oncological skin conditions. The firm’s portfolio of treatment devices includes the SRT-100, SRT-100+, and SRT-100 Vision. Its main product superficial radiation therapy (SRT), a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating basal cell and squamous cell skin cancers, and other skin conditions, such as keloids.
Featured Articles
- Get a free copy of the StockNews.com research report on Sensus Healthcare (SRTS)
- CVS Health is Growing into an Integrated Healthcare Organization
- Is C3.ai Stock a ChatGPT Artificial Intelligence Play?
- NVIDIA Outlook Improving: Watchlist Candidate for 2023
- Which Wireless Stock Should You Buy in 2023?
- Is Virgin Galactic Stock Preparing for Lift-Off?
Want to see what other hedge funds are holding SRTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sensus Healthcare, Inc. (NASDAQ:SRTS – Get Rating).
Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.